Trial Profile
Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2013
Price :
$35
*
At a glance
- Drugs Farletuzumab (Primary)
- Indications Pituitary adenoma
- Focus Therapeutic Use
- 07 Feb 2011 Actual initiation date (Feb 2011) added as reported by ClinicalTrials.gov.
- 07 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 Nov 2010 Planned initiation date changed from 1 Sep 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.